Raia Drogasil S.A.
RADLY
Other OTC3.85
USD
-0.08
- -
ISIN
US7507231089
CUSIP
750723108
Return %
Stock
S&P500
1Y
18.83
18.65
3Y
-25.96
71.44
5Y
-20.45
70.60
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Renato Raduan
- Full Time Employees
- 73,895
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- Av. Corifeu de Azevedo Marques, 3097 São Paulo SP Brazil 05339-900
- IPO Date
- Jul 19, 2016
- Website
- rdsaude.com.br
- Similar Companies
- Business
- Raia Drogasil S.A. (RADLY) operates as Brazil's largest pharmacy chain, engaging in the retail sale of medicines including branded, generic, over-the-counter, and specialty drugs; perfumery; personal hygiene and beauty products; cosmetics; and dermocosmetics, supplemented by health and beauty aids, household items, and private label brands. The company sells through over 3,000 Raia- and Drogasil-branded stores across all 27 Brazilian states, supported by 14 distribution centers, telesales, call centers, mobile apps, and e-commerce platforms that accounted for 15% of 2023 retail revenues; it also functions as a pharmacy benefit manager offering prenegotiated medical purchases and provides ancillary services via subsidiaries and investments such as Manipulaê for on-site compounded medications, Vitat for comprehensive health promotion, Labi Exames for laboratory analysis and vaccines, and Amplimed for electronic medical records. Founded in 2011 through the merger of Droga Raia (established 1905) and Drogasil (established 1935), Raia Drogasil maintains headquarters in São Paulo, Brazil, at Av. Corifeu de Azevedo Marques, 3097, Butantã, and employs approximately 59,000 people while serving urban and rural customers nationwide. Recent developments include a leadership transition in early 2025 with Renato Raduan assuming the presidency from Marcilio Pousada, who became board president; ongoing store expansion with 88 new pharmacies opened in Q3 2025 to boost market share; a 62% surge in digital sales during the same period; and accelerated growth from GLP-1 medication sales following the May 2025 launch of Mounjaro in Brazil, prompting UBS to upgrade its stock rating to Buy in October 2025.
Company News
Raia Drogasil S.A. (RADLY) Q2 2026 Earnings Call Transcript
Raia Drogasil S.A. (RADLY) Q1 2026 Earnings Call Transcript
Short Interest in Raia Drogasil S.A. (OTCMKTS:RADLY) Increases By 138.8%
Raia Drogasil S.A. (RADLY) Q4 2025 Earnings Call Transcript
Raia Drogasil S.A. (OTCMKTS:RADLY) Short Interest Update
Raia Drogasil S.A. (RADLY) Q3 2025 Earnings Call Transcript
Invesco International Small-Mid Company Fund Q3 2025 Top Contributors And Detractors
Raia Drogasil: Valuation Burn Now, Healthy Gains Later
What's Hot, What's Not: China Stocks Are Out. Top Picks From 3 Other Countries
3 Stocks to Ride the Latin America Market Boom in 2024
The 3 Best South American Stocks to Buy in 2023